慢性乙型肝炎患者CD14highCD16+单核细胞表达特点研究

肝脏 ›› 2016, Vol. 21 ›› Issue (10): 819-822.

慢性乙型肝炎患者CD14^highCD16⁺单核细胞表达特点研究

黄昂, 闫伟伟, 张纪元, 王福生, 邹正升

100039 北京解放军第三○二医院非感染性肝病诊疗与研究中心(黄昂,闫伟伟,邹正升),感染性疾病诊疗与研究中心(张纪元,王福生)

收稿日期:2016-06-29 发布日期:2020-06-18
通讯作者: 邹正升,Email:zszou302@163.com
基金资助:
军队医学科技青年培育计划(15QNP084)

Characterization and significance of CD14^highCD16⁺ monocytes in chronic hepatitis B patients

HUANG Ang, YAN Wei-wei, ZHANG Ji-yuan, WANG Fu-sheng, ZOU Zheng-sheng

Center of Non-infectious Liver Diseases, PLA 302 Hospital, Beijing 100039, China

Received:2016-06-29 Published:2020-06-18
Contact: ZOU Zheng-sheng, Email: zszou302@163.com

摘要/Abstract

摘要： 目的探讨慢性乙型肝炎(CHB)患者外周血中CD14^highCD16⁺单核细胞频率、功能特点以及与疾病进程之间的关系。方法利用荧光抗体标记结合多色流式技术,检测CHB患者外周血CD14^highCD16⁺单核细胞频率及表面TLR2分子的表达,用LPS刺激及细胞内染色方法检测CHB患者外周血CD14^highCD16⁺单核细胞产生细胞因子的能力。结果 CHB患者外周血的CD14^highCD16⁺单核细胞频率明显高于健康对照;CHB患者CD14^highCD16⁺单核细胞频率与ALT呈负相关(R=0.739, P<0.01),与HBV DNA载量成正相关(R =-0.283, P=0.008);CHB患者外周血CD14^highCD16⁺单核细胞上TLR2的表达高于其他两个亚群;免疫活化CHB患者外周血在LPS刺激后,CD14^highCD16⁺单核细胞亚群分泌IL-6的能力均高于CD14^highCD16^-和CD14^lowCD16⁺单核细胞亚群。结论 CD14^highCD16⁺单核细胞可能在清除肝炎病毒及肝脏免疫损伤中起重要作用。

关键词: 慢性乙型肝炎, CD16, Toll样受体2, 单核细胞

Abstract: Objective To investigate the expression characteristics of CD14^highCD16⁺ monocytes and its relationship with disease progression in patients with chronic hepatitis B virus (HBV) infection. Methods Immunofluorescent staining and flow cytometry assay were used to measure the frequency of CD14^highCD16⁺ monocytes and its expression of toll-like receptor 2 (TLR2) from CHB patients. Interleukin-6 (IL-6) production in CD14^highCD16⁺ monocytes stimulated with lipopolysaccharide (LPS) was also measured in CHB group. Results Frequency of CD14^highCD16⁺ monocytes in peripheral blood of CHB patients was significantly higher than those in health controls and CHB patients in immune tolerant phase. Proportions of circulating CD14^highCD16⁺ monocytes were positively correlated with serum alanine transaminase levels (R=0.739, P<0.01), while negatively correlated with HBV DNA loads (R=-0.283, P=0.008). CD14^highCD16⁺ monocytes showed increased expression of TLR2 compared with other subpopulations. After LPS stimulation, CD14^highCD16⁺ monocytes produced significantly more IL-6 than that in CD14^highCD16^- and CD14^lowCD16⁺ monocytes. Conclusion CD14^highCD16⁺ monocytes might play an important role in the pathogenesis of HBV-induced liver injury.

Key words: Chronic hepatitis B; CD16; TLR2; Monocytes

黄昂, 闫伟伟, 张纪元, 王福生, 邹正升. 慢性乙型肝炎患者CD14^highCD16⁺单核细胞表达特点研究[J]. 肝脏, 2016, 21(10): 819-822.

HUANG Ang, YAN Wei-wei, ZHANG Ji-yuan, WANG Fu-sheng, ZOU Zheng-sheng. Characterization and significance of CD14^highCD16⁺ monocytes in chronic hepatitis B patients[J]. Chinese Hepatolgy, 2016, 21(10): 819-822.

参考文献

[1] Wolk K, Hoflich C, Zuckermann-Becker H, et al. Reduced monocyte CD86 expression in postinflammatory immunodeficiency. Crit Care Med, 2007, 35: 458-467.
[2] Barlage S, Gnewuch C, Liebisch G, et al. Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation. Intensive Care Med, 2009, 35: 1877-1885.
[3] Zheng J, Liang H, Xu C, et al. An unbalanced PD-L1/CD86 ratio in CD14(++)CD16(+) monocytes is correlated with HCV viremia during chronic HCV infection. Cell Mol Immunol, 2014, 11: 294-304.
[4] Han J, Wang B, Han N, et al. CD14(high)CD16(+) rather than CD14(low)CD16(+) monocytes correlate with disease progression in chronic HIV-infected patients. J Acquir Immune Defic Syndr, 2009, 52: 553-559.
[5] Waschbisch A, Schroder S, Schraudner D, et al. Pivotal Role for CD16+ Monocytes in Immune Surveillance of the Central Nervous System. J Immunol, 2016, 196: 1558-1567.
[6] Amoruso A, Sola D, Rossi L, et al. Relation among anti-rheumatic drug therapy, CD14(+)CD16(+) blood monocytes and disease activity markers (DAS28 and US7 scores) in rheumatoid arthritis: A pilot study. Pharmacol Res, 2016, 107: 308-314.
[7] Lastrucci C, Benard A, Balboa L, et al. Tuberculosis is associated with expansion of a motile, permissive and immunomodulatory CD16(+) monocyte population via the IL-10/STAT3 axis. Cell Res, 2015, 25: 1333-1351.
[8] Kawai T, Akira S. Antiviral signaling through pattern recognition receptors. J Biochem, 2007, 141: 137-145.
[9] Cooper A, Tal G, Lider O, et al. Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J Immunol, 2005, 175: 3165-3176.
[10] Bezemer GF, Sagar S, van Bergenhenegouwen J, et al. Dual role of Toll-like receptors in asthma and chronic obstructive pulmonary disease. Pharmacol Rev, 2012, 64: 337-358.

[1]	钟大明, 蓝柏钊, 欧超兰, 陈开革, 温静, 李嘉丽, 周甦, 莫穆隆, 梁柱石. HBsAg不同载量的HBeAg阳性慢性乙型肝炎对恩替卡韦治疗应答比较[J]. 肝脏, 2020, 25(5): 505-507.
[2]	孙蔚, 杨星. 瞬时弹性成像和声脉冲辐射力成像技术诊断慢性乙型肝炎肝纤维化的价值[J]. 肝脏, 2020, 25(5): 534-535.
[3]	卢君瑶, 王登宇, 尹东林, 白玉盘, 许洁. HBV相关肝细胞癌的临床特征及危险因素分析[J]. 肝脏, 2020, 25(3): 285-287.
[4]	沈张平, 王钦君, 季沈杰. 血清miR127-3P与原发性肝癌的相关性研究[J]. 肝脏, 2020, 25(3): 302-305.
[5]	薛宏丽. HBsAg定量在慢性乙型肝炎治疗中的意义[J]. 肝脏, 2020, 25(3): 308-310.
[6]	梅栖榕, 杨丽, 沈毅. 慢性乙型肝炎患者长期服用阿德福韦酯与肾性低磷血症的相关性[J]. 肝脏, 2020, 25(3): 311-313.
[7]	孔媛媛, 魏巍, 单姗, 马红, 欧晓娟, 徐小元, 段钟平, 侯金林, 魏来, 尤红, 贾继东, 中国消除乙肝临床科研平台(CR-HepB)研究组. 乙型肝炎肝硬化患者的临床特征与抗病毒治疗模式变化[J]. 肝脏, 2020, 25(2): 123-127.
[8]	江海洋, 顾生旺, 刘欢, 姬腾飞, 蒋兆荣, 吴刚, 穆小苏. 基于1 783例慢性乙型肝炎患者长期随访的结果对大幅度提高其临床治愈的思考[J]. 肝脏, 2020, 25(2): 169-171.
[9]	陈攀丽, 唐建荣, 付雪芹, 张逸强, 胡景岚, 吴小力. Hp阳性监测在慢性乙型肝炎合并消化性溃疡患者中的临床意义[J]. 肝脏, 2020, 25(2): 184-185.
[10]	黄菁, 张永臣, 虞玲. 外周血Th17相关炎性因子在慢性乙型肝炎患者接受Peg-IFNα治疗前后的变化及临床意义[J]. 肝脏, 2020, 25(2): 194-196.
[11]	马春明, 张锁才, 史罗明, 吴剑明, 周根法, 郑剑. 慢性乙型肝炎初治后转换恩替卡韦干预的耐药及疗效观察[J]. 肝脏, 2020, 25(2): 208-211.
[12]	张郴华, 钟备, 邓英, 李敏. 慢性乙型肝炎患者HBV核苷(酸)类似物预存耐药基因突变的研究[J]. 肝脏, 2020, 25(1): 39-41.
[13]	贾瑾堂, 施文娟, 王兆勋, 田鹏飞. 乙型肝炎慢加急性肝衰竭患者血清γ干扰素水平变化的意义[J]. 肝脏, 2020, 25(1): 61-62.
[14]	王倩倩, 胡乾坤, 张毅, 方钟, 黄晨璐, 许伟, 陈良, 黄玉仙. 抗-HBc半定量水平联合早期病毒学应答预测干扰素治疗慢性乙型肝炎的疗效[J]. 肝脏, 2019, 24(9): 1002-1006.
[15]	刘薇, 袁海霞, 时强. 抗病毒治疗慢性乙型肝炎肝硬化后肝纤维化逆转情况观察[J]. 肝脏, 2019, 24(9): 1055-1057.